综述了定性和定量研究药物—蛋白结合作用的部分方法，包括色谱、毛细管电泳、核磁共振光谱、质谱等方法及一些传统方法如平衡透析、超滤等方法，并讨论了各自的优点和局限性。

研究了正庚基锂、正辛基锂同6，6- 二烷基富烯反应的立体和溶剂效应对反应类型的影响。在弱极性溶剂中（方法A，B），正庚基锂、正辛基锂同6，6- 二烷基富烯主要发生加成反应；在极性溶剂中（方法C），则倾向于加成和还原两种反应。利用上述反应形成的环戊二烯基阴离子同TiCl4、ZrCl4反应，合成了一系列新的取代茂钛、锆化合物。

The EOF pump was successfully used as a means of introducing samples into a capillary system. An improved sample injection device has been developed using a TeflonTM union(TU) to link the two capillaries together. The capillary applied high voltage served as the EOF pump to pull the liquid inside while the other one served the purposes of isolating the electric field. Using the bias degree(BD) and SD of bias(SDB), it was possible to quantitatively determine the sampling bias and evaluate the effectiveness of injection approaches in bias elimination. Several related factors were evaluated, and it was found that TU approach could fully eliminate the bias under the optimal conditions. The fracture did not affect the efficiency, leak, or dilute the sample significantly. This approach was effective under both normal and reverse EOF situations and adapted to real samples. Finally, a TU method using grounded injection electrode was proposed and shown to be suitable for samples with low conductivity and high injection voltage.

报道了双（1- 正戊基环己基茂）二氯化钛[(η5- C5H4C(CH2)5(C5H11- n)]2TiCl2(Ⅰ)及双（1- 甲基- 1-（α- 噻吩基）乙基环戊二烯基）二氯化钛[η5- C5H4C(CH3)2- ？？]2TiCl2(Ⅱ)的晶体结构和分子结构。二者均系单斜晶系，（Ⅰ）的空间群为P2/ n，晶胞参数a= 14.180(2)，b= 6.562(1)，c= 17.046(3) A，β= 99.63(1)°，Z= 2，V= 1563.8 A3，Dx= 1.188 g/ cm3，F(000)= 596，Mr= 553.56，λ= 0.71073 A，μ=4.59 cm-1，R= 0.058，Rw= 0.066；(Ⅱ)的空间群为C2/ c，晶胞参数a= 25.713(1)，b= 6.617(1)，c= 13.591(1) A，β= 92.78(2)°，Z= 4，V= 2309.8 A3, Dx= 1.430 g/ cm3，Mr= 497.41，λ= 0.71073 A．μ= 7.822 cm-1，F(000)= 1032，R= 0.055，Rw= 0.072。茂环上取代基对茂环金属化合物的结构产生较大影响，空间阻碍的增大使得取代基与茂环相连C- C单键增长。

A method of capillary electrophoresis frontal analysis (CEFA) is developed for the first time to study the binding of ketoprofen to human serum albumin (HSA) and compared with high performance liquid chromatography frontal analysis (LCFA). The separation is performed in an uncoated fused-silica capillary (60-cm × 75-μm i.d., 50-cm effective length) with a phosphate buffer (pH 7.4, ionic strength of 0.17M) as the running buffer. The applied voltage is 13 kV and the detection is set at 254 nm. A trapezoidal peak of the unbound ketoprofen appears after HSA elution in the electropherogram. The plateau height of the peak is employed to determine the unbound concentration of ketoprofen in the HSA equilibrated sample solution. The CEFA method provides the advantages of small sample injection volume and rapidity and the disadvantage of low sensitivity compared with LCFA. CEFA is applicable to the binding parameter estimation of ketoprofen to the secondary binding site; an association c:onstant (K2) of 0.24 × 106M-1 and the number for the binding site per molecule HSA of 2.54 is estimated. In contrast, LCFA measures parameters for both primary and secondary sites, which are 1.05 ×106M-l and 0.94 for K1 and n1, respectively, and 0.12 × 106M-1 and 3.16 for K2 and n2, respectively. It is found that ketoprofen binds mainly at the primary site at a molecular ratio of ketoprofen versus HSA lower than 0.75, and the binding at the secondary site occurs at a higher ratio.